Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
09:10am, Thursday, 05'th Sep 2024
Regeneron is an innovative drugmaker that continues to perform well. Shopify's changed and improved business should lead to stronger returns.
Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
09:17pm, Wednesday, 04'th Sep 2024
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 11:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor R
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
12:16pm, Tuesday, 27'th Aug 2024
REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
Regeneron Stock: Valuation Now Demands More Growth
03:10pm, Monday, 26'th Aug 2024
Regeneron Pharmaceuticals stock reached new all-time highs this month, driven by the Eylea franchise returning to growth in the second quarter, and despite minor regulatory setbacks for the oncology p
HRMY or REGN: Which Is the Better Value Stock Right Now?
12:46pm, Monday, 26'th Aug 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks offers
Approval of Ordspono is based on data demonstrating robust and durable responses in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, including in the post-CAR-T setting
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
01:00am, Monday, 26'th Aug 2024
20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)
Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug
08:20am, Wednesday, 21'st Aug 2024
Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.
US FDA declines to approve Regeneron's blood cancer therapy
07:17pm, Tuesday, 20'th Aug 2024
The U.S. Food and Drug Administration declined to approve Regeneron's therapy for a common form of blood cancer, the company said on Tuesday.
Regeneron Provides Update on Biologics License Application for Linvoseltamab
06:45pm, Tuesday, 20'th Aug 2024
TARRYTOWN, N.Y., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter
2 Biotech Stocks To Watch In August 2024
08:36pm, Tuesday, 13'th Aug 2024
Biotech stocks to keep on your radar this month.
7 Stocks That Usually Benefit From a Recession
04:30pm, Tuesday, 13'th Aug 2024
As the dark clouds of a potential recession loom on the horizon, investors are scrambling to find safe havens for their hard-earned money. While it's true that most stocks tend to suffer during econom
3 Biotech Stocks Poised for a Comeback After Last Week's Market Meltdown
07:30am, Tuesday, 13'th Aug 2024
Due to their sometimes speculative nature, biotech stocks are especially sensitive to broader market corrections like the one experienced last week. This can be exceptionally stressful for investors,
HRMY vs. REGN: Which Stock Is the Better Value Option?
12:40pm, Friday, 09'th Aug 2024
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks presents investo
3 Biotech Stocks With Promising Drug Pipelines: August 2024
06:40am, Thursday, 08'th Aug 2024
Investing in biotech stocks with promising pipelines has to be the most exciting area of the market. A successful drug approval can not only unveil a blockbuster treatment worth billions of dollars, b
